A Phase I first-in-human study to evaluate the safety and pharmacokinetic (PK) properties of the intravenously (IV) administered OMN6, a novel antimicrobial peptide targeting Acinetobacter baumannii (A. baumannii), in adults including older healthy volunteer (HV) subjects
Acinetobacter baumannii (A. baumannii) is an opportunistic Gram-negative pathogen that is listed as of critical priority on the World Health Organization (WHO) Priority Pathogen list.